Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights.
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
Immune checkpoints are potential regulators of immune system which are crucial for self-tolerance and cell immunity. Further, these have critical role in the progression of cancer and thus, have emerged out to be potential therapeutic target for drug development. Since the approval of first immune checkpoint inhibitor, Yervoy in 2011 for the management of metastatic melanoma, there has been rapid influx of other immune checkpoint inhibitors in the market. Globally, there are 16 approved immune checkpoint inhibitors which mainly target programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T-lymphocyte associated antigen -4 (CTLA-4).
As per our report findings, the PD-1/PD-L1 inhibitors is expected to show dominance in the global market which can be attributed to the increased volume of research activities, approvals, and rise in prescriptions of these drugs such as Nivolumab and Pembrolizumab. Furthermore, increasing in sales of the drug Keytruda (Pembrolizumab) since its entry in 2014 due to its proven efficiency to treat multiple FDA-Approved indications like melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and others which are highly prevalent globally driving the growth of the segment market. Apart from this, several other potential PD-1/PD-L1 inhibitors are also present in late stages of clinical development which are expected to enter the market in forthcoming years.
Further advancement in the field of immune checkpoint therapy and considerable research activities has also led to identification of a few other immune checkpoints which also have potential for anticancer immunotherapy such as lymphocyte activation gene-3 (LAG-3), T-cell membrane protein-3, signal transducer and activator of transcription 3 (STAT3), T cell immunoglobulin and ITIM domain (TIGIT), and glucocorticoid-induced tumor necrosis factor receptor (TNFR) family related protein (GITR). Among this, TIGIT and LAG-3 have gained the maximum interest and several inhibitors targeting these immune checkpoints have entered the clinical development. Relatlimab developed by Bristol Myers Squibb is one of the most promising LAG-3 under development, which is expected to enter the market by 2022.
The global immune checkpoint inhibitor market is moderately competitive. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, research collaboration, while others are investing in clinical trials to extend the treatment of other indications with the existing drugs to address the unmet challenges of the disease burden driving the market share. For instance, CStone Pharmaceuticals has announced collaboration with EQRx for two key late-stages immune-oncology assets, sugemalimab (anti-PD-1) and CS1003 (anti-PD-1). Under the agreement, EQRx will obtain exclusive rights to lead global development and commercialization worldwide, excluding Mainland China, Taiwan, Hong Kong and Macau. CStone retains rights to CS1003 in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug.
As per our report findings, the global immune checkpoint inhibitor market is expected to surpass US$ 300 Billion by 2028. The primary factor attributing to the growth of the market is a steep rise in the global prevalence of various types of cancers coupled with a steep increase in the geriatric population across the geographical locations, mainly in developed and emerging economies. Thus, the rise in target patients, increased awareness among the people along with their earlier detection of cancer using technologically advanced screening procedures are likely to boost the growth of market during the forecast period.
Our report provides comprehensive analysis on the globally approved immune checkpoint inhibitors in the market along with their commercial information including price, dosage, and sales analysis. The report also gives in-depth analysis on the ongoing clinical trials in the global market and the major key drugs in research and development.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com